RNASEK and pancreatic adenocarcinoma: The results from the GEPIA database revealed that RNASEK was significantly upregulated (P < 0.05) in cholangiocarcinoma (CHOL) and pancreatic adenocarcinoma (PAAD) (Appendix A).